# reload+after+2024-01-20 17:45:29.975769
address1§3675 Market Street
city§Philadelphia
state§PA
zip§19104
country§United States
phone§267 817 5790
website§https://www.centurytx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
fullTimeEmployees§163
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Michael C. Diem M.D.', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 650659, 'exercisedValue': 0, 'unexercisedValue': 438161}, {'maxAge': 1, 'name': 'Dr. Adrienne  Farid Ph.D.', 'age': 61, 'title': 'COO & Head of Early Development', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 650659, 'exercisedValue': 0, 'unexercisedValue': 627608}, {'maxAge': 1, 'name': 'Mr. Brent  Pfeiffenberger M.B.A., Pharm.D.', 'title': 'CEO & Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gregory  Russotti Ph.D.', 'age': 56, 'title': 'Chief Technology & Manufacturing Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kenneth J. Dow J.D.', 'title': 'Senior VP of General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Shane  Williams Ph.D.', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hyam I. Levitsky M.D.', 'age': 65, 'title': 'President of Research & Development', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 502125, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Michael  Naso Ph.D.', 'title': 'Senior VP of Cell Engineering', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nick  Trede M.D., Ph.D.', 'title': 'Senior VP & Head of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas  Carr CPA', 'title': 'Senior VP of Finance & Operations and Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§4
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.353
priceToSalesTrailing12Months§76.717705
currency§USD
dateShortInterest§1702598400
forwardEps§-2.23
pegRatio§0.1
exchange§NMS
quoteType§EQUITY
shortName§Century Therapeutics, Inc.
longName§Century Therapeutics, Inc.
firstTradeDateEpochUtc§1624023000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f95000f0-82eb-31c4-9606-6aa49d9bac06
gmtOffSetMilliseconds§-18000000
targetHighPrice§22.0
targetLowPrice§10.0
targetMeanPrice§14.67
targetMedianPrice§13.5
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§8.376
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
